RPL5P13

Across TCGA pan-cancer cohorts, RPL5P13 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL5P13’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RPL5P13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL5P13 is over-expressed in tumor, although a few such as KIRP show the opposite, repressed pattern.

BLCA, BRCA, and STAD are the cancer types where RPL5P13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL5P13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.213	.031	4	view →
BRCA	Female	All	+0.160	.034	4	view →
STAD	All	All	+0.157	.015	3	view →
COAD	All	II,III,IV	+0.025	.044	1	view →
KIRP	Male	All	−0.016	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL5P13–BLCA

Open the BLCA breakdown →